Partnering for Innovation in Manufacturing & Supply

How are bio/pharma companies and their partners collaborating to resolve the difficult challenges that arise in development, manufacturing, and the supply chain? DCAT Member Companies are invited to apply to share fresh insights, best practices, and lessons learned at a DCAT Week program. Applications close January 13, 2025.

How are bio/pharma companies and their partners collaborating to resolve the difficult challenges that arise in development, manufacturing, and the supply chain? DCAT Member Companies are invited to apply to share fresh insights, best practices, and lessons learned at a DCAT Week program. Applications deadline extended and closes January 24, 2025.

By Patricia Van Arnum, Editorial Director, DCAT, pvanarnum@dcat.org

A solutions-based program at DCAT Week
Innovation is essential for achieving operational excellence and delivering value. A DCAT Week 2025 program, Partnering for Innovation in Manufacturing & Supply, will feature case studies on how bio/pharma companies and their partners have collaborated to resolve the hard challenges that arise in development, manufacturing, and the supply chain. Partner companies include CDMOs/CMOs, suppliers of raw materials or other inputs, technology services providers, or other companies, including other bio/pharma companies.

The 90-minute program will consist of three co-presentations (20 minutes each) between a bio/pharma company and partner company. It is a way to share fresh insights, best practices, and lessons learned to a well-informed business audience of senior to mid-level executives.

DCAT Member Companies are invited to submit applications by January 24, 2025, for consideration of their case study.  A task force of industry colleagues selected from DCAT volunteer committees and leadership will evaluate all applications and select three case studies providing the most useful, valuable, and innovative insight of utility and interest to DCAT Member Companies. Presentations will be due March 3, 2025. Further information, including the online application to apply, may be found here.

Topics of interest
The case studies may address a range of topics—but must reflect an innovative or better approach taken in manufacturing or supply. Potential topics can include:

  • New technologies in drug-substance and drug-product manufacturing or packaging;
  • Cost optimization and improved production economics;
  • Collaborative project management;
  • Increasing supply-chain performance, resiliency, or visibility;
  • Upgraded inventory management;
  • Collaborative demand and supply planning/forecasting;
  • Sustainability improvements: technology, manufacturing & metrics;
  • Digitalization to better performance, including regulatory compliance; or
  • Other innovation in manufacturing and supply.

The program provides a way to stand out among your peers in the industry by showing  resourceful and effective ways to advance manufacturing and supply. Further information, including the online application to apply, may be found here.

Recent Feature Articles

Upcoming DCAT European Conference: Expedition Pharma: Innovation from a Patient-First Perspective   

By
How is innovation inspiring and fueling the transformation of the bio/pharma industry?DCAT’s conference and networking event, Expedition Pharma: Innovation from a Patient-First Perspective, being held June 4–5, 2025, in Lugano, Switzerland, will provide key insights.  

The Bio/Pharma Majors’ Strategies & Products: Where Do Small-Molecule Drugs Rank?

By
How do small-molecule drugs rank in the strategy of the bio/pharmaceutical majors? What are the leading products from a revenue perspective, and what are key developments on a commercial and pipeline basis? DCAT Value Chain Insights looks at what may in store for 2025.

CDMO/CMO Outlook: What May Be in Store for 2025

By
What are key issues shaping the market for bio/pharmaceutical outsourcing in the coming year? DCAT Value Chain Insights takes an inside look into the market drivers, trends, and key activity shaping the CDMO/CMO market.

Will the ADC Wave Continue in 2025?

By
Deal-making by the large pharma companies in antibody drug conjugates (ADCs) to build their in product portfolios in oncology has been on the upsurge, but will the ADC wave continue in 2025? A look at recent deals and what may lie ahead.